tiprankstipranks
Trending News
More News >

Grand Pharmaceutical Group Reports Strong 2024 Financial Performance and Strategic Growth

Story Highlights
Grand Pharmaceutical Group Reports Strong 2024 Financial Performance and Strategic Growth

Confident Investing Starts Here:

Grand Pharmaceutical Group Limited ( (HK:0512) ) has shared an announcement.

Grand Pharmaceutical Group Limited reported a significant financial performance for the year ended December 31, 2024, with a 10.6% increase in revenue and a 31.3% rise in profit attributable to its owners. The company has made substantial investments in research and development, particularly in its nuclear medicine segment, which saw a 176.6% revenue increase. This growth reflects the company’s strategic focus on innovation and expansion amid China’s evolving pharmaceutical landscape, characterized by systemic reforms and increased emphasis on innovative drugs.

More about Grand Pharmaceutical Group Limited

Grand Pharmaceutical Group Limited operates within the pharmaceutical industry, focusing on the development and commercialization of innovative medical products. The company is involved in research and development, particularly in the nuclear medicine anti-tumor diagnosis and treatment segment, and aims to enhance its market presence through strategic expansion and innovation.

YTD Price Performance: 10.42%

Average Trading Volume: 3,642,419

Technical Sentiment Consensus Rating: Sell

Current Market Cap: HK$18.81B

For a thorough assessment of 0512 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App